ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 913

Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis

Alan Rathbun1, Michelle Shardell 2, Joseph Gallo 3, Alice Ryan 1, Elizabeth Stuart 3, Megan Schuler 4, Michelle Yau 5 and Marc C. Hochberg 1, 1University of Maryland School of Medicine, Baltimore, MD, 2National Institute on Aging, Baltimore, MD, 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 4RAND Corporation, Boston, MA, 5Hebrew SeniorLife Institute for Aging Research, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: analgesics and Chronic pain, depression, Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S106: Osteoarthritis – Clinical I: Innovations (909–914)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Depression often accompanies knee osteoarthritis (OA), exacerbating the severity and persistence of pain, and may negatively affect clinical outcomes associated with analgesic treatment. This study evaluated whether depression moderates (Figure 1) the effectiveness of analgesics on knee pain severity in knee OA.

Methods: Eligible participants (n=1,477) were identified from the Osteoarthritis Initiative and were not using analgesics (acetaminophen, non-steroidal anti-inflammatory drugs, or opioids) at baseline (time t) and had radiographic disease (Kellgren-Lawrence [K-L] grade 2, 3, or 4) at the first annual follow-up visit (time t+1). Analgesic initiation and utilization was assessed at the first three annual follow-up visits (time t+1, time t+2, time t+3), and depression was evaluated concurrent to analgesic use with the Center for Epidemiological Studies Depression (CES-D) scale and corresponding screening threshold (CES-D score ≥ 16). Knee pain severity from the second to the fourth annual follow-up visit (time t+2, time t+3, time t+4) was measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale (rescaled range = 0-100). Time-invariant and time-varying confounders measured at time t and time t+1, time t+2, and time t+3 were age, sex, race, education, marital status, employment, health insurance, smoking, alcohol consumption, Charlson comorbidity index, and symptomatic knee OA status; and K-L grade, body mass index, physical performance, knee injuries, knee injections, and WOMAC pain score, respectively. Structural nested mean models appropriate for evaluating time-varying effect moderation were implemented using an inverse-probability-of-treatment-weighting regression-with-residuals approach.

Results: In non-depressed participants, analgesic treatment at years one, two, and three had minimal effect (Table 1) on knee pain severity at years two, three, and four, respectively, and time-specific associations ranged from -1.16 (95% CI: -3.48, 1.16) to 0.76 (95% CI: -1.67, 3.18). Moreover, persistent use of analgesics did not increase the magnitude of the treatment effect in non-depressed participants. By contrast, time-specific treatment effects in depressed participants increased during follow-up from -0.42 (95% CI: -7.56, 6.72) to -15.51 (95% CI: -26.13, -4.89), and the association between year three analgesic use and year four knee pain severity was statistically significant. The magnitude of the associations increased with persistent analgesic use in depressed participants, primarily due to significant effect moderation concerning year three analgesic use, where the subsequent difference in treatment effect between depressed and non-depressed participants was -16.27 (95% CI: -27.12, -5.42).

Conclusion: Findings indicate a statistically and clinically significant greater one-year treatment effect of analgesic use that lowered knee pain severity in persons with knee OA and depression. Thus, OA patients with depression may derive more benefit from analgesic treatment for chronic knee pain than non-depressed patients, perhaps because their pain is undertreated.


Figure_1

Figure 1


Table_1

Table 1


Disclosure: A. Rathbun, None; M. Shardell, None; J. Gallo, None; A. Ryan, None; E. Stuart, None; M. Schuler, RAND Corportation, 3; M. Yau, None; M. Hochberg, Bioiberica SA, 5, Bone Therapeutics, 5, BriOri Biotech, 4, Bristol Myers Squibb, 5, Eli Lilly, 5, Elsevier, 7, EMD Serono, 5, EMD Serono Research and Development Institute, Inc., 5, Galapagos, 5, Galapagos, IQVIA and Hoffman LaRoche, 9, IBSA Biotechniq SA, 5, Novartis Pharma AG, 5, Pfizer, 5, Pfizer Inc, 5, Plexxikon, 5, Regenosine, Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., and Zynerba, 5, Rheumcon, Inc, 3, Samumed LLC, 5, Theralogix LLC, 4, 5, TissueGene Inc, 5, UpToDateTM, 7.

To cite this abstract in AMA style:

Rathbun A, Shardell M, Gallo J, Ryan A, Stuart E, Schuler M, Yau M, Hochberg M. Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/depression-as-a-moderator-of-analgesic-effectiveness-in-knee-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-as-a-moderator-of-analgesic-effectiveness-in-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology